-
公开(公告)号：US11091427B2
公开(公告)日：2021-08-17
申请号：US16497299
申请日：2018-03-23
IPC分类号： C07C227/12 , C07C229/48 , C07D265/32 , C07D265/34 , C07K5/08 , C07K7/06
摘要： This invention relates to a method for producing an alkenyl 1-aminocyclopropane-1-carboxylic acid of Formula I wherein R1 is a protecting group, n is an integer between 1 and 10, and A and B are chiral centres such that when A is S, B is R and when A is R, B is S. The method comprises a stereoselective formation of the cyclopropane moiety by cycloaddition onto a double bond, in a molecule comprising a chiral template, Formula lc. Further provided is the use of Formula I in the production of stapled peptides.
-
公开(公告)号：US11072795B2
公开(公告)日：2021-07-27
申请号：US16345487
申请日：2017-10-16
发明人： Uttam Surana , Dave Keng Boon Wee , Jing Lin , Bing Lim
IPC分类号： C12N15/11 , C12N15/113 , A61P35/00 , A61K9/00 , A61K31/7088 , A61K45/06 , C12Q1/6886 , A61K31/7125 , A61K31/712
摘要： The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided.
-
公开(公告)号：US20210223249A1
公开(公告)日：2021-07-22
申请号：US15999378
申请日：2017-02-16
发明人： Ptrick TAN , Wen Fong OOl
IPC分类号： G01N33/574 , G01N33/53 , G01N33/563
摘要： The present invention relates to a method for determining the presence or absence of at least one super-enhancer in a cancerous biological sample based on signal intensity of the histone modification H3K27ac. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method of determining the susceptibility of a subject to cancer or a gastrointestinal disease and a method of predicting cancer cell survival or cancer cell viability by determining the presence or absence of at least one super-enhancer. The present invention also relates to inhibitors of CDX2 and/or HNF4α, such as metformin, and use thereof for modulating the activity of a super-enhancer.
-
公开(公告)号：US20210212314A1
公开(公告)日：2021-07-15
申请号：US17215700
申请日：2021-03-29
发明人： James L. Hedrick , Mareva B. Fevre , Nathaniel H. Park , Victoria A. Piunova , Yi Yan Yang , Pang Kern Jeremy Tan
IPC分类号： A01N25/10 , A01N43/50 , A01N37/26 , C07C279/10 , C08L79/02 , C08G69/26 , C08G73/02 , A01N47/44 , C08L101/00
摘要： Techniques regarding chemical compounds with antimicrobial functionality are provided. For example, one or more embodiments describe herein can comprise a monomer that can comprise a molecular backbone. The molecular backbone can comprise a bis(urea)guanidinium structure covalently bonded to a functional group, which can comprise a radical. Also, the monomer can have supramolecular assembly functionality.
-
公开(公告)号：US11058110B2
公开(公告)日：2021-07-13
申请号：US16829370
申请日：2020-03-25
发明人： Mareva B. Fevre , James L. Hedrick , Nathaniel H. Park , Victoria A. Piunova , Pang Kern Jeremy Tan , Chuan Yang , Yi Yan Yang
摘要： Techniques regarding polymers with antimicrobial functionality are provided. For example, one or more embodiments described herein can regard a polymer, which can comprise a repeating ionene unit. The repeating ionene unit can comprise a cation distributed along a degradable backbone. The degradable backbone can comprise a terephthalamide structure. Further, the repeating ionene unit can have antimicrobial functionality.
-
公开(公告)号：US11053496B2
公开(公告)日：2021-07-06
申请号：US16310395
申请日：2017-06-14
发明人： Prabha Sampath , Sundaram Gopinath , Shan Quah
IPC分类号： A61K48/00 , C07H21/04 , C12N15/113 , A61P35/04 , A61P35/00 , A61K31/713
摘要： The present invention refers to a method of treating a carcinoma by administration of one or more of an oligonucleotide comprising the sequence of miR-198 (SEQ ID NO: 1) or a functional part thereof, or an oligonucleotide which reduces expression of Follistatin-related protein 1 (FSTL1), Protein diaphanous homolog 1 (DIAPH1), Laminin subunit gamma-2 (LAMC2) or Urokinase-type plasminogen activator (PLAU). Preferably, the at least one or more oligonucleotides directed against FSTL1, DIAPH1, LAMC2 or PLAU is a shRNA or siRNA. Also provided is a method of determining the presence of carcinoma in a subject, comprising detecting and comparing the presence of miR-198 and/or at least one of FSTL1, DIAPH1, LAMC2 or PLAU, miR-181a, epidermal growth factor (EGF), and epidermal growth factor receptor (EGFR), and comparing the detected levels with that in a control sample.
-
公开(公告)号：US20210203023A1
公开(公告)日：2021-07-01
申请号：US16090163
申请日：2017-03-29
发明人： Mein Jin TAN , Bing LI , Xian Jun LOH , Yun ZONG , Zhao LIU , Xiao Ming GE
IPC分类号： H01M12/02 , H01M12/08 , H01M4/38 , H01M4/86 , H01M4/90 , H01M4/96 , H01G9/042 , H01G13/00 , H01G9/035
摘要： This invention relates to an electrochemical cell comprising an anode structure comprising an element selected from the group consisting of group 1, group 2, group 8, group 12 and group 13 of the Periodic Table of Elements; a cathode structure comprising a catalyst; and a hydrogel located between the anode structure and the cathode structure. In a preferred embodiment, the cell comprises the anode of Zinc, the catalyst of CoOx/C, the hydrogel of free-standing alkaline polyacrylamide hydrogel, wherein said hydrogel was first synthesized via UV-initiated radical polymerization of acrylamides, followed by exchange of water with an alkaline electrolyte of potassium hydroxide (KOH). The invention further relates to a method of manufacturing such an electrochemical cell and the use of a hydrogel in a metal/air battery.
-
公开(公告)号：US11040978B2
公开(公告)日：2021-06-22
申请号：US16432469
申请日：2019-06-05
IPC分类号： C07D487/04 , C07D235/06 , C07D471/04 , C07D519/00 , A61K45/06 , A61K31/4184 , A61K31/437 , A61K31/4985 , A61K31/5025 , A61K31/519 , A61P35/00 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/551 , A61K31/553 , C07D471/10 , C07D491/107
摘要： The present invention relates to compounds of Formula (Ib-I) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.
-
公开(公告)号：US20210155991A1
公开(公告)日：2021-05-27
申请号：US16977197
申请日：2019-03-01
发明人： Anders SKANDERUP , Guo YU , Sarah NG
IPC分类号： C12Q1/6886 , C12Q1/6827
摘要： There is provided a method of determining a risk of gastrointestinal cancer in a human subject, the method comprising: determining in a biological sample of the subject, whether mutation is present in at least one CTCF-binding sites (CBS) overlapping regions, or portions or flanking sequences thereof, or at least one non-CBS regions, or portions or flanking sequences thereof, wherein presence of mutation in at least one CBS overlapping regions, or portions or flanking sequences thereof, and/or at least one non-CBS regions, or portions or flanking sequences thereof, is indicative of a risk of gastrointestinal cancer in the subject. There are also provided a method of treating gastrointestinal cancer in a human subject and related kits.
-
公开(公告)号：US11018080B2
公开(公告)日：2021-05-25
申请号：US16087621
申请日：2017-03-17
IPC分类号： H01L23/498 , H01L23/538 , H01L21/48 , H01L23/31 , H01L25/065 , H01L25/00 , H01L23/00
摘要： Various embodiments may provide a semiconductor package. The semiconductor package may include a routing layer including a plurality of first layer contact elements on a first side and a plurality of second layer contact elements on a second side opposite the first side, and a first semiconductor die including a plurality of first electrical die contact elements coupled to the plurality of first layer contact elements. The semiconductor package may further include a second semiconductor die including a plurality of second electrical die contact elements coupled to the plurality of second layer contact elements, and a mold structure covering the second semiconductor die. A first pitch between neighbouring first electrical die contact elements may be greater than a second pitch between neighbouring second electrical die contact elements.
-
-
-
-
-
-
-
-
-
搜索结果
2171 条记录 (耗时 0.036 秒)
